Lipid-modifying pharmacotherapy in diabetes mellitus: A protocol for a systematic review and network meta-analysis of randomised trials
Xudong Zhao, Cheng Tang, Tianqi Yuan, Jiafan Chen, Cuijuan Shi, Xiaoyu Liu, Ruigeng Yang, Yushang Zhi · 2026
Read Lipid-modifying pharmacotherapy in diabetes mellitus: A protocol for a systematic review and network meta-analysis of randomised trials by Xudong Zhao, Cheng Tang, Tianqi Yuan, Jiafan Chen, Cuijuan Shi, Xiaoyu Liu, Ruigeng Yang, Yushang Zhi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0354259.txt.
Description
Zhao and colleagues present a 2026 protocol for a review comparing cholesterol drugs in people with diabetes. Diabetes sharply raises the risk of clogged arteries and heart death, and the menu of lipid drugs keeps growing: statins, fibrates, absorption blockers, and newer injectable and oral classes. Which works best and safest for diabetic patients, head to head, is unsettled.
The planned network review will search the major trial databases with no language limits, keeping only randomized trials that compare these drugs alone or in combination. Two reviewers will screen and judge quality separately. Main outcomes are heart events; secondary outcomes include blood fat levels, heart biomarkers, risk scores, and side effects. Certainty will be graded with a network-specific framework, and results published for peer review. As a protocol, the paper promises a method, not an answer; the ranking of drugs awaits the review itself.
Catalog record
| CREATOR | Xudong Zhao, Cheng Tang, Tianqi Yuan, Jiafan Chen, Cuijuan Shi, Xiaoyu Liu, Ruigeng Yang, Yushang Zhi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30073 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |